Steven Dabbs
GlaxoSmithKline (United Kingdom)(GB)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Synthesis and Biological Evaluation, Chemical Synthesis and Analysis, Cancer therapeutics and mechanisms, Phenothiazines and Benzothiazines Synthesis and Activities
Most-Cited Works
- → A Novel, Potent, and Selective 5-HT7Antagonist: (R)-3-(2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970)(2000)249 cited
- → (R)-3,N-Dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzenesulfonamide: The First Selective 5-HT7Receptor Antagonist(1998)102 cited
- → Biarylcarbamoylindolines Are Novel and Selective 5-HT2C Receptor Inverse Agonists: Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent(2000)79 cited
- → Novel and Selective 5-HT2C/2B Receptor Antagonists as Potential Anxiolytic Agents: Synthesis, Quantitative Structure−Activity Relationships, and Molecular Modeling of Substituted 1-(3-Pyridylcarbamoyl)indolines(1998)64 cited
- → Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases(2013)63 cited
- → 5-Hydroxytryptamine (5-HT3) receptor antagonists. 2. 1-Indolinecarboxamides(1990)55 cited
- → Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases(2011)51 cited
- → Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases(2016)46 cited
- → Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases(2011)46 cited
- → Synthesis, Biological Activity, and Molecular Modeling Studies of Selective 5-HT2C/2B Receptor Antagonists(1996)31 cited